Investor mix
10 investors on record; lead investors include RA Capital Management, BridgeBio; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 4 | 40% |
| Private equity | 2 | 20% |
| Accelerator & incubator | 1 | 10% |
| Other / undisclosed | 3 | 30% |
Developer of a small-molecule treatment solution for transthyretin amyloidosis
10 investors on record; lead investors include RA Capital Management, BridgeBio; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 4 | 40% |
| Private equity | 2 | 20% |
| Accelerator & incubator | 1 | 10% |
| Other / undisclosed | 3 | 30% |